Addex drug to start Phase 2 study in MDD

Wednesday 6 June 2012

Addex Therapeutics Ltd said that its partner, Janssen Pharmaceuticals Inc (Johnson & Johnson), is to start a Phase 2 study of an allosteric modulator for major depressive disorder, with anxiety symptoms. The same drug is being studied in schizophrenia.

Full text available to subscribers only. Click here for information on subscribing to MedNous.